On May 24, 2016, MilliporeSigma released survey results of 250 global biopharmaceutical executives on how their companies will manage new risks associated with the changing biopharma landscape, the company said in a press announcement. The survey, which was sponsored by MilliporeSigma, was conduOriginal Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.